🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia
Organization BECKMAN RESEARCH INSTITUTE/CITY OF HOPELocation DUARTE, UNITED STATESPosted 1 Dec 2023Deadline 16 Feb 2025 ⚠️
NIHUS FederalResearch GrantFY2025ALL1ALL1 geneAcetylationAchievementAchievement AttainmentAcute Lymphoblastic Leukemia Protein 1Acute leukemiaBindingBiochemicalBiotinC4HC3 Zinc FingerCRISPRCRISPR/Cas systemCXXC7Cancer GenesCancer-Promoting GeneCancersCell LineCellLineChIP SequencingChIP-seqChIPseqChimera ProteinChimeric ProteinsChromatinClassificationClinicalClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCombined Modality TherapyComplexDNA RearrangementDrosophila Homolog of TrithoraxEC 2.1.1Early-Stage Clinical TrialsElementsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessExhibitsFusion ProteinFutureGene Action RegulationGene ClusterGene ExpressionGene Expression RegulationGene RearrangementGene RegulationGene Regulation ProcessGene TranscriptionGenesGenetic ScreeningGenetic TranscriptionGenetics-MutagenesisHRXHistone AcetylaseHistone AcetylationHistone DeacetylationHistone H3HistonesHumanIn VitroKMT2AL-LysineLeftLibrariesLysineLysine-Specific Methyltransferase 2AMEIS1MEIS1 geneMLL fusion leukemiaMLL geneMLL leukemiaMLL rearrangedMLL rearrangementMLL-rearranged leukemiaMLL1Malignant NeoplasmsMalignant TumorMediatingMeis homeobox 1MethylationMethyltransferaseMixed Lineage Leukemia GeneMixed-Lineage LeukemiaMixed-Lineage Leukemia ProteinModern ManMolecularMolecular InteractionMultimodal TherapyMultimodal TreatmentMultiple lineage leukemia 1MutagenesisMutagenesis Molecular BiologyMyeloid-Lymphoid Leukemia GeneMyeloid-Lymphoid Leukemia ProteinMyeloid/Lymphoid Leukemia GeneMyeloid/Lymphoid Or Mixed Lineage Leukemia ProteinMyeloid/Lymphoid or Mixed Lineage Leukemia GeneOncogenesPDX modelPHD FingerPHD Finger MotifPatient derived xenograftPatientsPeptide DomainPeptidesPharmaceutical AgentPharmaceuticalsPharmacologic SubstancePharmacological SubstancePhase 1 Clinical TrialsPhase I Clinical TrialsPlant Homeodomain Type Zinc FingerPrognosisProtein DomainsProteinsProto Oncogene Proteins MLLPublishingRNA ExpressionReaderRegimenResearchRoleSIRT1SIRT1 geneScanningSirtuin 1Strains Cell LinesSurvival RateSystematicsTechniquesTechnologyTertiary Protein StructureTherapeuticTranscriptionTranscription ActivationTranscriptional ActivationTransforming GenesValidationVitamin HWorkWorld Health OrganizationZinc Finger Protein HRXcancer typechromatin immunoprecipitation coupled with sequencingchromatin immunoprecipitation followed by sequencingchromatin immunoprecipitation with sequencingchromatin immunoprecipitation-seqchromatin immunoprecipitation-sequencingcoenzyme Rcombination therapycombined modality treatmentcombined treatmentcultured cell linedensitydetermine efficacyefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationepigeneticallyevaluate efficacyexamine efficacyfunctional genomicsgenetic approachgenetic strategygenome scalegenome-widegenomewidehistone acetyltransferasehistone modificationimprovedin vivoinhibitorinnovateinnovationinnovativeleukemialeukemogenesismalignancymethylasemixed lineage leukemia 1multi-modal therapymulti-modal treatmentmutantneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachpatient derived xenograft modelpharmaceuticalpharmacologicphase I protocolpre-clinicalpreclinicalprogramsrecruitresponseresponse to therapyresponse to treatmentshRNAshort hairpin RNAsmall hairpin RNAsocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapy responsetransmethylasetreatment responsetreatment responsivenessvalidations
Applications closed.
Description preview
PROJECT SUMMARY/ABSTRACT
MLL-rearranged (MLL-r) leukemias account for 5-10% of human acute leukemia and is associated with
poor prognosis. The unmet clinical needs and the lack of an effective targeted therapy to the MLL-r
leukemias emphasize the need for novel regimens. Recent cancer epigenetics studies discovered a central
role for the histone…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click